Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
JAZZ 
Jazz Pharmaceuticals PLC (JAZZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: JAZZ (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
18 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $186.47
1 Year Target Price $186.47
| 10 | Strong Buy |
| 6 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.8% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.68B USD | Price to earnings Ratio - | 1Y Target Price 186.47 |
Price to earnings Ratio - | 1Y Target Price 186.47 | ||
Volume (30-day avg) 18 | Beta 0.24 | 52 Weeks Range 95.49 - 148.06 | Updated Date 09/16/2025 |
52 Weeks Range 95.49 - 148.06 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.97 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -9.91% | Operating Margin (TTM) 20.94% |
Management Effectiveness
Return on Assets (TTM) 5.19% | Return on Equity (TTM) -10.84% |
Valuation
Trailing PE - | Forward PE 6.36 | Enterprise Value 11438969690 | Price to Sales(TTM) 1.88 |
Enterprise Value 11438969690 | Price to Sales(TTM) 1.88 | ||
Enterprise Value to Revenue 2.8 | Enterprise Value to EBITDA 30.73 | Shares Outstanding 60658800 | Shares Floating 58660101 |
Shares Outstanding 60658800 | Shares Floating 58660101 | ||
Percent Insiders 3.11 | Percent Institutions 105.98 |
Upturn AI SWOT
Jazz Pharmaceuticals PLC
Company Overview
History and Background
Jazz Pharmaceuticals PLC was founded in 2003 and has grown through acquisitions and internal development, focusing on specialty pharmaceuticals. Key milestones include the acquisition of EUSA Pharma in 2012 and Celator Pharmaceuticals in 2016.
Core Business Areas
- Sleep: Develops and commercializes treatments for sleep disorders, including narcolepsy and idiopathic hypersomnia.
- Oncology: Focuses on treatments for hematologic malignancies and solid tumors.
- Other: Includes royalties and contract manufacturing revenues.
Leadership and Structure
Bruce Cozadd is the Executive Chairman and Daniel Swisher is the Chief Executive Officer. The company operates with a functional organizational structure, divided by therapeutic area and supporting functions.
Top Products and Market Share
Key Offerings
- Revenue Data (USD millions): 1676
- Xyrem/Xywav: A treatment for narcolepsy. Xywav has become a dominant product. Competitors include generic sodium oxybate and other stimulants.
- Epidiolex/Epidyolex: A cannabidiol (CBD) oral solution for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. Competitors include other anti-epileptic drugs.
- Revenue Data (USD millions): 736
- Revenue Data (USD millions): 399
- Rylaze: Treatment for acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). Competitors include other chemotherapeutic agents.
Market Dynamics
Industry Overview
The pharmaceutical industry is driven by innovation, regulatory approvals, and patent protection. It faces challenges such as increasing competition, pricing pressures, and evolving regulatory landscapes.
Positioning
Jazz Pharmaceuticals PLC is positioned as a specialty pharmaceutical company with a focus on niche markets and innovative therapies. Its competitive advantages include a strong portfolio of approved products, a robust pipeline, and a dedicated sales force.
Total Addressable Market (TAM)
The combined TAM for Jazz Pharmaceutical's target therapeutic areas (sleep disorders, oncology, epilepsy) is estimated to be in the tens of billions of dollars. Jazz is positioned with key products and growth drivers (e.g., Xywav, Rylaze) to address a portion of this TAM.
Upturn SWOT Analysis
Strengths
- Strong portfolio of approved products
- Focus on niche markets
- Experienced management team
- Robust pipeline
- Strong revenue
Weaknesses
- Reliance on key products
- Exposure to generic competition
- Regulatory risks
- High debt level
- Limited geographic diversity
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions
- Geographic expansion
- Pipeline maturation
- Positive clinical trial outcomes
Threats
- Generic competition
- Pricing pressures
- Regulatory changes
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- GWPH
- AMGN
- TEVA
- ENDP
Competitive Landscape
Jazz Pharmaceuticals PLC competes with a variety of pharmaceutical companies in its target therapeutic areas. It differentiates itself through innovative therapies, a strong commercial presence, and a focus on niche markets.
Major Acquisitions
Celator Pharmaceuticals
- Year: 2016
- Acquisition Price (USD millions): 1500
- Strategic Rationale: Expanded Jazz Pharmaceuticals' oncology portfolio with the addition of Vyxeos for the treatment of acute myeloid leukemia.
Cavendish Biosciences
- Year: 2024
- Acquisition Price (USD millions): 47.5
- Strategic Rationale: Enhances early-stage neuroscience R&D with innovative peptide technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by product launches and strategic acquisitions.
Future Projections: Future growth is projected to be driven by new product launches and expansion into new markets. Analyst estimates vary, but generally project continued revenue growth.
Recent Initiatives: Recent strategic initiatives include acquisitions of companies with complementary pipelines, clinical trial advancements, and expansion of the commercial footprint.
Summary
Jazz Pharmaceuticals is a specialty pharmaceutical company with a solid portfolio of niche products, especially in sleep disorders and oncology. Its reliance on a few key products and increasing competition pose challenges, however acquisitions and pipeline development support future growth. Strong financial performance and experienced management bolster its position and they should beware of market competitors. Current strategic initiatives are positive for their future growth trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jazz Pharmaceuticals PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2007-06-01 | President, COO, CEO & Director Ms. Renee D. Gala | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2800 | Website https://www.jazzpharma.com |
Full time employees 2800 | Website https://www.jazzpharma.com | ||
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.